We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > MAH

News List

What is MAH policy in China? ChatGPT/PharmaSources
November 09, 2023
In China, the Marketing Authorization Holder (MAH) system refers to a policy shift in the regulation of pharmaceutical products.
Suggesting on the best practice of becoming MAH of a drug in China ChatGTP/PharmaSources
November 09, 2023
Becoming a Marketing Authorization Holder (MAH) for a drug in China involves navigating a complex regulatory landscape.
First company awarded market authorisation under new Chinese drug law europeanpharmaceuticalreview
January 07, 2020
The mAb tislelizumab has been granted approval from Chinese authorities, making Boehringer Ingelheim Biopharmaceuticals the first MAH under the new system.
New China-based biotechs fueling growth in manufacturing across China cphi-online
April 11, 2019
New China-based biotechs fueling growth in manufacturing across China
STA Pharmaceutical sees rapid growth in MAH Programs in China pharmaasia
December 27, 2017
Since the launch of the MAH pilot, STA has undertaken eight development programmes, and anticipates carrying on 10+ MAH projects in 2018.